Last updated: 3 July 2019 at 3:30am EST

Dr. Floyd E. Bloom Net Worth




The estimated Net Worth of Floyd E Bloom is at least $8.39 Million dollars as of 16 July 2018. Dr Bloom owns over 20,000 units of Alkermes plc stock worth over $3,398,914 and over the last 13 years he sold ALKS stock worth over $4,990,678.

Dr Bloom ALKS stock SEC Form 4 insiders trading

Dr has made over 17 trades of the Alkermes plc stock since 2011, according to the Form 4 filled with the SEC. Most recently he sold 20,000 units of ALKS stock worth $879,000 on 16 July 2018.

The largest trade he's ever made was selling 30,094 units of Alkermes plc stock on 31 January 2013 worth over $697,278. On average, Dr trades about 10,003 units every 85 days since 2011. As of 16 July 2018 he still owns at least 127,923 units of Alkermes plc stock.

You can see the complete history of Dr Bloom stock trades at the bottom of the page.





Dr. Floyd E. Bloom biography

Dr. Floyd E. Bloom is the Founder at Alkermes plc.



How old is Dr Bloom?

Dr Bloom is 83, he's been the Founder of Alkermes plc since . There are 1 older and 21 younger executives at Alkermes plc. The oldest executive at Alkermes plc is Dr. Floyd E. Bloom M.D., 84, who is the Founder.

What's Dr Bloom's mailing address?

Floyd's mailing address filed with the SEC is Connaught House, Burlington Rd, Dublin 4, Ireland.

Insiders trading at Alkermes plc

Over the last 13 years, insiders at Alkermes plc have traded over $407,046,771 worth of Alkermes plc stock and bought 86,119 units worth $2,034,840 . The most active insiders traders include Corp Plc Elan Science Three..., Richard F Pops, and James M Frates. On average, Alkermes plc executives and independent directors trade stock every 5 days with the average trade being worth of $1,083,232. The most recent stock trade was executed by David Joseph Gaffin on 3 August 2024, trading 2,014 units of ALKS stock currently worth $53,512.



What does Alkermes plc do?

alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (cns) diseases. the company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. headquartered in dublin, ireland, alkermes plc has an r&d center in waltham, massachusetts; a research and manufacturing facility in athlone, ireland; and a manufacturing facility in wilmington, ohio. for more information, please visit alkermes’ website at www.alkermes.com.



Complete history of Dr Bloom stock trades at Alkermes plc

Insider
Trans.
Transaction
 Total value
Floyd E Bloom
Director
 Sale $879,000
16 Jul 2018
Floyd E Bloom
Director
 Option $228,800
12 Sep 2017
Floyd E Bloom
Director
 Option $365,800
8 Feb 2016
Floyd E Bloom
Director
 Option $280,800
6 Apr 2015
Floyd E Bloom
Director
 Sale $1,342,400
15 Jan 2015
Floyd E Bloom
Director
 Option $335,400
28 Aug 2014
Floyd E Bloom
Director
 Sale $461,600
7 May 2014
Floyd E Bloom
Director
 Sale $430,600
8 Jan 2014
Floyd E Bloom
Director
 Sale $819,400
26 Dec 2013
Floyd E Bloom
Director
 Option $236,800
7 May 2013
Floyd E Bloom
Director
 Option $127,680
11 Apr 2013
Floyd E Bloom
Director
 Option $6,720
2 Apr 2013
Floyd E Bloom
Director
 Option $134,400
28 Mar 2013
Floyd E Bloom
Director
 Sale $697,278
31 Jan 2013
Floyd E Bloom
Director
 Option $143,800
14 Sep 2012
Floyd E Bloom
Director
 Buy $351,800
26 Apr 2012
Floyd E Bloom
Director
 Sale $360,400
28 Oct 2011


Alkermes plc executives and stock owners

Alkermes plc executives and other stock owners filed with the SEC include: